Key points are not available for this paper at this time.
Use of BMDs to measure outcomes is becoming the norm rather than the exception in many fields. Yet, trialists need to account for several methodological issues when specifying and conducting RCTs using these novel tools.
Possamai et al. (2020) studied this question.